Home

Applications

APPLICATIONS OVERVIEW
DRUG DISCOVERY
ADME-Tox
Biochemical Assays
Cell-based Assays
HTS and Secondary Screening
Microsampling
Protein Crystallography
RNAi
Sample Management
CANCER RESEARCH
Personalized Medicine
Functional Screening / DSRT
RNAi
Sequencing
Single-cell Genomics
GENOMIC RESEARCH
Gene Expression
Genotyping
Microbiome
qPCR
Sequencing
Single-cell Genomics
Synthetic Biology

Products

LIQUID HANDLING
LIQUID HANDLERS OVERVIEW
Echo® 525 Liquid Handler
Echo® 555 Liquid Handler
Echo® 550 Liquid Handler
Echo® 520 Liquid Handler
AUTOMATION
AUTOMATION OVERVIEW
Access™ Laboratory Workstation
Tempo™ Automation Control Software
SOFTWARE APPLICATIONS
SOFTWARE OVERVIEW
Echo® Array Maker
Echo® Cherry Pick
Echo® Combination Screen
Echo® Compliance Manager
Echo® Dose-Response
Echo® Plate Audit
Echo® Plate Reformat
CONSUMABLES
CONSUMABLES OVERVIEW
Echo® Qualified Microplates
Labcyte® Assay Microplates
MicroClime® Environmental Lid
Echo® Qualified Reservoir

Technology

Echo® Acoustic Liquid Handling
Dynamic Fluid Analysis™
Acoustic Mass Spectrometry
Direct Dilution

News / Events

Labcyte BLOG
Upcoming Events
Press Releases
Labcyte in the News
Labcyte Community

Resources

JALA Special Issue
Publications
Articles and Other Media
Application Notes
Posters
Webinars
Videos
Customer Profiles
Core Labs

Support

Brochures
Web Documentation*
User Guides*
Quick Start Guides*
Specification Sheets
Site Prep Guides
Service and Maintenance
Request Information

Company

About Us
Echo® Acoustic Technology
Leadership Team
Meet Labcyte
Careers
Contact and Location
Privacy Policy

Picoliter Inc. Announces $22 Million Financing

Abingworth and Sprout Group Lead Funding

July 09, 2002

Mountain View, CA

Mountain View, CA, July 9, 2002—Picoliter Inc. announced today that the company has raised $22 million in a Series B financing.  Picoliter has developed ultrasound-based technology for transferring very small volumes of fluid with high precision.  The company’s unique fluid handling and analysis technology addresses a number of critical life science and drug discovery markets that in total exceed $1 billion.  The co-lead investors, Abingworth and Sprout Group, will be represented on the company’s board of directors by Dr. Jonathan MacQuitty and Mr. Vijay Lathi.

“The Series B financing is another important milestone in the evolution of Picoliter.  The funds will allow us to expand our product development and manufacturing teams and focus on additional applications of our breakthrough technology,” commented Dr. Elaine J. Heron, Chairman and CEO of Picoliter.  “We are delighted that Abingworth and Sprout Group, each with long histories in supporting successful life science firms, joined existing investors Delphi Ventures, Alloy Ventures, and Palo Alto Investors in this round.”

“In its first two years Picoliter has demonstrated application of its technology for liquid handling with biological materials, compound libraries and manufacturing of both arrays and particles,” stated Dr. Jonathan MacQuitty, President of Abingworth Management, Inc.  “Building on their strong fundamental understanding of ultrasonics, the company has filed 30 U.S. patent applications covering general use of the technology for life science tools as well as targeted, high-value applications like protein crystallization, pharmaceutical particle manufacturing and sample preparation for mass spectrometry.  The company is now developing products for applications based on several of its inventions.”

"PicoliterTM technology has two powerful advantages over all other liquid handling approaches,” noted Vijay Lathi, Principal of the Sprout Group.  “First, the ability to dispense fluid samples with no contact and second, the ability to reliably transfer volumes as tiny as a picoliter (10-12 liter).  Because these advantages will be critical to improving many processes, including high throughput screening, cell-based screening and DNA array production, we believe that the markets for Picoliter products are substantial and growing."

The company also announced successful installation of one of its acoustic drop ejection systems at Hosokawa Micron Group in Osaka, Japan. Picoliter and Hosokawa are working to together to further develop applications of the ADE technology for the production of small, uniform and multi-layer particles for pharmaceutical manufacturing.

About Picoliter Inc.
Picoliter Inc. is a development stage company located in Mountain View, CA.  The company has developed a novel technology for moving and analyzing small amounts of liquid using ultrasound energy.  The PicoliterTM liquid handling technology has broad applications in the life science tools market including microarrays, dispensing equipment, and living cell transfer devices.

Members of the Picoliter management team have successfully brought a wide variety of products based on new technologies to market.  The company includes individuals with experience in senior management, array/consumables manufacturing, business development, intellectual property protection and product development at Affymetrix, Applied Biosystems, Eastman Kodak, Incyte, International Paper, Molecular Dynamics, Packard Instruments, Symyx, and Xerox PARC.

About Abingworth
Abingworth is an independent venture firm founded in 1973 and is a key player among life science venture capital investors on both sides of the Atlantic, having offices in London and Palo Alto. Abingworth has funds under management of close to $400 million and seven experienced professionals with operational and venture capital expertise. It has backed more than 75 life science/medical companies, most of which have gone public or been acquired. For further information on Abingworth and its portfolio companies please visit www.abingworth.com.

About the Sprout Group
The Sprout Group is one of the oldest and largest venture capital firms in the US.  Since 1969, Sprout has helped finance more than 300 companies with combined sales exceeding $40 billion.  With offices in Menlo Park, New York and Chicago, Sprout focuses on helping to grow companies in datacom and telecom, technology-related services, enterprise software, and healthcare technology. Sprout Group is a venture capital affiliate of Credit Suisse First Boston.  For further information on the Sprout Group, please visit their web site at www.sproutgroup.com.




MAIN CONTACT
LABCYTE INC.
170 Rose Orchard Way
San Jose, California 95134
USA
Tel:
+1 408 747-2000
Toll-free:
+1 877 742-6548
Sales:
+1 877 742-6548, option 1
Fax:
+1 408 747-2010
Contact:
REQUEST INFO

PRESS CONTACT
Nicole Litchfield
Bioscribe, Inc.
Tel:
+1 415 793-6468
Email:
nicole@bioscribe.com
TOP